JAK2 and diffuse large B-cell lymphoma: There are several potential mechanisms for aberrant JAK2/STAT3 activation in DLBCL tumors including cytokines such as IL-10 [8], loss of negative regulators such as tyrosine phosphatases, and genetic mutations.